

Geographic Atrophy

The study of a new medicine (RO7303359) in people with a type of eye disease (geographic atrophy secondary to age-related macular degeneration)

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT04615325 GR42163

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This clinical trial was done to study a new medicine called, "RO7303359", for the treatment of an eye disease: geographic atrophy secondary to age-related macular degeneration. Men and women at least 50 years old who had the eye disease and met other conditions could take part in this study. Researchers wanted to find out what the side effects of RO7303359 were. They also wanted to find the highest dose that people could tolerate.

Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland) Sponsor	Phase 1 Phase
--	-------------------------

NCT04615325 GR42163
Trial Identifiers

Eligibility Criteria:

Gender All	Age ≥50 Years	Healthy Volunteers No
----------------------	-------------------------	---------------------------------
